Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis
- Qureight’s AI-powered quantitative imaging analytics platform and services to analyse HRCT images to evaluate changes in compartment-specific lung biomarkers
- The focus of these efforts will be on the quantitative assessment of change from baseline in lung fibrosis